XML 71 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jul. 05, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Jun. 30, 2016
Oct. 31, 2015
Financial assets and liabilities subject to fair value measurements            
Transfer of assets from Level 1 to Level 2   $ 0        
Transfer of assets from Level 2 to Level 1   0        
Assets:            
Fair value of assets   311,700 $ 144,754      
Liabilities:            
Contingent consideration payable   25,400 269,722      
Derivative liability     265      
Deferred compensation plan liability   2,258 1,479      
Fair value of liabilities   27,658 271,466      
Contingent consideration payable            
Balance, beginning of the period   269,722 274,077      
Payment of contingent consideration in cash   (10,000) (5,000)      
Payment of contingent consideration in stock     (6,115)      
Unrealized change in fair value change during the period, included in Statement of Operations   (234,322) 6,760 $ 4,377    
Balance, end of the period   25,400 269,722 $ 274,077    
Callidus            
Liabilities:            
Contingent consideration payable   25,400        
MiaMed Inc            
Contingent consideration payable            
Asset acquisition, potential aggregate deal value $ 89,500          
Clinical and Regulatory Approval milestones | Callidus            
Liabilities:            
Contingent consideration payable   25,000        
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc            
Liabilities:            
Contingent consideration payable upon achievement of milestones 83,000          
Contingent consideration payable            
Contingent consideration payable upon achievement of milestones $ 83,000          
Commercial paper            
Assets:            
Fair value of assets   79,803 68,390      
Asset-backed securities            
Assets:            
Fair value of assets   30,287        
Corporate debt securities            
Assets:            
Fair value of assets   199,012 74,535      
Money market funds            
Assets:            
Fair value of assets   2,598 1,829      
Level 2            
Assets:            
Fair value of assets   311,700 144,754      
Liabilities:            
Derivative liability     265      
Deferred compensation plan liability   2,258 1,479      
Fair value of liabilities   2,258 1,744      
Level 2 | Commercial paper            
Assets:            
Fair value of assets   79,803 68,390      
Level 2 | Asset-backed securities            
Assets:            
Fair value of assets   30,287        
Level 2 | Corporate debt securities            
Assets:            
Fair value of assets   199,012 74,535      
Level 2 | Money market funds            
Assets:            
Fair value of assets   2,598 1,829      
Level 3            
Liabilities:            
Contingent consideration payable   25,400 269,722      
Fair value of liabilities   $ 25,400 $ 269,722      
Level 3 | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus            
Liabilities:            
Discount rate (as a percent)   11.50%        
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus            
Liabilities:            
Probability of achievement of milestones (as a percent)   71.00%        
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus            
Liabilities:            
Probability of achievement of milestones (as a percent)   100.00%        
Redmile Group | October 2015 Notes and Warrants Purchase Agreement | Private Placement Purchase Agreement            
Financial assets and liabilities subject to fair value measurements            
Debt Instrument, Face Amount           $ 50,000
Redmile Group | Additional Note and Warrant Agreement June 2016 | Beneficial Owner | Private Placement Purchase Agreement            
Financial assets and liabilities subject to fair value measurements            
Debt Instrument, Face Amount         $ 30,000